

Olli Kampman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/905040/publications.pdf>

Version: 2024-02-01

95
papers

1,864
citations

236925

25
h-index

302126

39
g-index

97
all docs

97
docs citations

97
times ranked

2803
citing authors

#	ARTICLE	IF	CITATIONS
1	Indicators of medication compliance in first-episode psychosis. <i>Psychiatry Research</i> , 2002, 110, 39-48.	3.3	143
2	Can onset and recovery in depression be predicted by temperament? A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2011, 135, 20-27.	4.1	117
3	5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. <i>NeuroReport</i> , 2009, 20, 1125-1128.	1.2	103
4	Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. <i>Neuroscience Letters</i> , 2010, 477, 105-108.	2.1	69
5	Effects of S-Ketamine as an Anesthetic Adjuvant to Propofol on Treatment Response to Electroconvulsive Therapy in Treatment-Resistant Depression. <i>Journal of ECT</i> , 2013, 29, 158-161.	0.6	68
6	Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. <i>Psychiatry Research</i> , 2014, 218, 277-283.	3.3	56
7	Catechol-O-methyltransferase and Monoamine Oxidase A Genotypes and Drug Response to Conventional Neuroleptics in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 429-434.	1.4	44
8	Neuregulin genotype and medication response in Finnish patients with schizophrenia. <i>NeuroReport</i> , 2004, 15, 2517-2520.	1.2	44
9	Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 303-307.	5.7	42
10	Prevalence of metabolic syndrome in subjects with melancholic and non-melancholic depressive symptoms. A Finnish population-based study. <i>Journal of Affective Disorders</i> , 2012, 136, 543-549.	4.1	40
11	Meta-Analysis of Anxiety Disorders and Temperament. <i>Neuropsychobiology</i> , 2014, 69, 175-186.	1.9	40
12	Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. <i>BMC Psychiatry</i> , 2007, 7, 22.	2.6	39
13	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 65.	2.6	38
14	P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT. <i>Neuroscience Letters</i> , 2011, 493, 127-130.	2.1	37
15	Association of EGF polymorphism with schizophrenia in Finnish men. <i>NeuroReport</i> , 2004, 15, 1215-1218.	1.2	36
16	TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. <i>Neuroscience Letters</i> , 2010, 468, 80-84.	2.1	34
17	Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. <i>European Neuropsychopharmacology</i> , 2003, 13, 147-151.	0.7	32
18	Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia. <i>Neuroscience Letters</i> , 2006, 407, 195-198.	2.1	32

#	ARTICLE	IF	CITATIONS
19	Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. <i>Psychiatry Research</i> , 2010, 176, 85-87.	3.3	32
20	Association between vitamin b12 levels and melancholic depressive symptoms: a Finnish population-based study. <i>BMC Psychiatry</i> , 2013, 13, 145.	2.6	32
21	Anxiety Disorders and Temperament—an Update Review. <i>Current Psychiatry Reports</i> , 2017, 19, 27.	4.5	32
22	One-Year Follow-Up After Discontinuing Maintenance Electroconvulsive Therapy. <i>Journal of ECT</i> , 2012, 28, 225-228.	0.6	31
23	Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 95-102.	3.2	29
24	NOTCH4 gene promoter polymorphism is associated with the age of onset in schizophrenia. <i>Psychiatric Genetics</i> , 2003, 13, 61-63.	1.1	28
25	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. <i>Journal of Neural Transmission</i> , 2019, 126, 35-45.	2.8	27
26	Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. <i>Neuroscience Letters</i> , 2011, 501, 20-24.	2.1	26
27	Pessimism and risk of death from coronary heart disease among middle-aged and older Finns: an eleven-year follow-up study. <i>BMC Public Health</i> , 2016, 16, 1124.	2.9	26
28	Apolipoprotein E polymorphism is associated with age of onset in schizophrenia. <i>Journal of Human Genetics</i> , 2004, 49, 355-359.	2.3	25
29	Patient characteristics and diagnostic discrepancy in first-episode psychosis. <i>Comprehensive Psychiatry</i> , 2004, 45, 213-218.	3.1	22
30	Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. <i>Human Psychopharmacology</i> , 2007, 22, 211-215.	1.5	22
31	ACE polymorphism and response to electroconvulsive therapy in major depression. <i>Neuroscience Letters</i> , 2009, 458, 122-125.	2.1	20
32	Interaction of tumor necrosis alpha G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 279-283.	3.2	19
33	Association of Income With the Incidence Rates of First Psychiatric Hospital Admissions in Finland, 1996-2014. <i>JAMA Psychiatry</i> , 2020, 77, 274.	11.0	19
34	BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression. <i>Psychiatric Genetics</i> , 2013, 23, 134-136.	1.1	18
35	Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: Susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression. <i>Neuroscience Letters</i> , 2015, 590, 116-120.	2.1	17
36	RGS4 polymorphism and response to electroconvulsive therapy in major depressive disorder. <i>Neuroscience Letters</i> , 2008, 437, 25-28.	2.1	16

#	ARTICLE	IF	CITATIONS
37	Leisure-time physical activity and metabolic syndrome plus depressive symptoms in the FIN-D2D survey. <i>Preventive Medicine</i> , 2010, 51, 466-470.	3.4	16
38	Lifetime leisure-time physical activity and the risk of depressive symptoms at the ages of 65-74 years: The FIN-D2D survey. <i>Preventive Medicine</i> , 2012, 54, 313-315.	3.4	16
39	Polymorphism in alpha 2A adrenergic receptor gene is associated with sialorrhea in schizophrenia patients on clozapine treatment. <i>Human Psychopharmacology</i> , 2014, 29, 336-341.	1.5	16
40	SERT and NET polymorphisms, temperament and antidepressant response. <i>Nordic Journal of Psychiatry</i> , 2015, 69, 531-538.	1.3	16
41	Pessimism, diet, and the ability to improve dietary habits: a three-year follow-up study among middle-aged and older Finnish men and women. <i>Nutrition Journal</i> , 2018, 17, 92.	3.4	16
42	Effect of electroconvulsive therapy on brain-derived neurotrophic factor levels in patients with major depressive disorder. <i>Brain and Behavior</i> , 2018, 8, e01101.	2.2	15
43	Dopamine receptor D2 141C Insertion/Deletion polymorphism in a Finnish population with schizophrenia. <i>Psychiatry Research</i> , 2003, 121, 89-92.	3.3	14
44	TPH1A218C polymorphism and temperament in major depression. <i>BMC Psychiatry</i> , 2013, 13, 118.	2.6	14
45	No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin. <i>Psychiatric Genetics</i> , 2013, 23, 33-35.	1.1	14
46	CYP1A2 polymorphism 1545C>T (rs2470890) is associated with increased side effects to clozapine. <i>BMC Psychiatry</i> , 2014, 14, 50.	2.6	14
47	Manifesto for an international digital mental health network. <i>Digital Psychiatry</i> , 2019, 2, 14-24.	2.1	14
48	Association between folate intake and melancholic depressive symptoms. A Finnish population-based study. <i>Journal of Affective Disorders</i> , 2012, 138, 473-478.	4.1	12
49	Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 89-95.	1.3	12
50	Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients. <i>European Neuropsychopharmacology</i> , 2017, 27, 442-449.	0.7	11
51	Acute Psychogeriatric Inpatient Treatment Improves Neuropsychiatric Symptoms but Impairs the Level of Functioning in Patients with Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 290-296.	1.5	10
52	Factors associated with subjective side-effects during clozapine treatment. <i>Nordic Journal of Psychiatry</i> , 2015, 69, 161-166.	1.3	10
53	Temperament and character profiles associated with depression and treatment response in patients with or without comorbid substance abuse. <i>Psychiatry Research</i> , 2016, 245, 250-258.	3.3	10
54	Low tumor necrosis factor-1 levels predict symptom reduction during electroconvulsive therapy in major depressive disorder. <i>Brain and Behavior</i> , 2018, 8, e00933.	2.2	10

#	ARTICLE	IF	CITATIONS
55	The effects of adiposity and alcohol use disorder on adipokines and biomarkers of inflammation in depressed patients. <i>Psychiatry Research</i> , 2018, 264, 31-38.	3.3	10
56	Relationships between depressive symptoms and self-reported unintentional injuries: the cross-sectional population-based FIN-D2D survey. <i>BMC Public Health</i> , 2012, 12, 516.	2.9	9
57	Behavioral activation versus treatment as usual in naturalistic sample of psychiatric patients with depressive symptoms: a benchmark controlled trial. <i>BMC Psychiatry</i> , 2018, 18, 238.	2.6	9
58	Outcome of patients with dual diagnosis in secondary psychiatric care. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 470-476.	1.3	8
59	The association of alcohol use and quality of life in depressed and non-depressed individuals: a cross-sectional general population study. <i>Quality of Life Research</i> , 2018, 27, 1217-1226.	3.1	8
60	<i>INSIG2</i> polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine. <i>Pharmacogenomics</i> , 2016, 17, 1987-1997.	1.3	7
61	Implementing physical exercise and music interventions for patients suffering from dementia on an acute psychogeriatric inpatient ward. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 401-408.	1.3	7
62	Status of inflammation and alcohol use in a 6-month follow-up study of patients with major depressive disorder. <i>Alcohol</i> , 2019, 81, 21-26.	1.7	7
63	Clozapine-Related Diarrhea and Colitis. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 293-296.	1.4	7
64	The reliability of compliance assessments performed by doctors and patients during neuroleptic treatment: a comparison of compliance ratings. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 299-304.	4.5	7
65	Psychiatric hospital admission and long-term care in patients with very-late-onset schizophrenia-like psychosis. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 355-360.	2.7	6
66	Electroconvulsive therapy increases temporarily plasma vascular endothelial growth factor in patients with major depressive disorder. <i>Brain and Behavior</i> , 2021, 11, e02001.	2.2	6
67	A Cluster Model of Temperament as an Indicator of Antidepressant Response and Symptom Severity in Major Depression. <i>Psychiatry Investigation</i> , 2014, 11, 18.	1.6	6
68	Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder. <i>Pharmacogenomics Journal</i> , 2022, 22, 166-172.	2.0	6
69	Temperament profiles, 5-HT2A genotype, and response to treatment with SSRIs in major depression. <i>Journal of Neural Transmission</i> , 2010, 117, 1431-1434.	2.8	5
70	Early assessment of implementing evidence-based brief therapy interventions among secondary service psychiatric therapists. <i>Evaluation and Program Planning</i> , 2015, 52, 182-188.	1.6	5
71	Genetic Polymorphisms Associated With Constipation and Anticholinergic Symptoms in Patients Receiving Clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 193-199.	1.4	5
72	Assessment of alcohol consumption in depression follow-up using self-reports and blood measures including inflammatory biomarkers. <i>Alcohol and Alcoholism</i> , 2019, 54, 243-250.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Impact of Comorbid Alcohol Use Disorder on Health-Related Quality of Life Among Patients With Depressive Symptoms. <i>Frontiers in Psychiatry</i> , 2021, 12, 688136.	2.6	5
74	Smoking and weight among patients using clozapine. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 620-625.	1.3	4
75	Temperament clusters associate with anxiety disorder comorbidity in depression. <i>Journal of Affective Disorders</i> , 2018, 236, 252-258.	4.1	4
76	Temperament and character profiles are associated with depression outcome in psychiatric secondary care patients with harmful drinking. <i>Comprehensive Psychiatry</i> , 2018, 84, 26-31.	3.1	4
77	Outcome of neuropsychiatric symptoms and daily functioning of patients with dementia treated on an acute psychogeriatric ward. <i>Nordic Journal of Psychiatry</i> , 2018, 72, 521-525.	1.3	4
78	What is important for the sustained implementation of evidence-based brief psychotherapy interventions in psychiatric care? A quantitative evaluation of a real-world programme. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 185-194.	1.3	4
79	The reliability of compliance assessments performed by doctors and patients during neuroleptic treatment: a comparison of compliance ratings. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 299-304.	4.5	3
80	BDNF and NRG1 polymorphisms and temperament in selective serotonin reuptake inhibitor-treated patients with major depression. <i>Acta Neuropsychiatrica</i> , 2018, 30, 168-174.	2.1	3
81	Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder. <i>Brain Sciences</i> , 2021, 11, 688.	2.3	3
82	Review: over 25% of people with schizophrenia, psychoses, or severe mental disorders fail to adhere to treatment programmes. <i>Evidence-Based Mental Health</i> , 2004, 7, 40-40.	4.5	2
83	Efficacy of electroconvulsive therapy: is it in the <i>BDNF</i> gene?. <i>Pharmacogenomics</i> , 2013, 14, 1365-1368.	1.3	2
84	Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine. <i>Psychiatry Research</i> , 2021, 306, 114227.	3.3	2
85	Sleep in Psychotic Disorders: Results From Nationwide SUPER Finland Study. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	2
86	Reaction Time and Visual Memory in Connection to Alcohol Use in Persons with Bipolar Disorder. <i>Brain Sciences</i> , 2021, 11, 1154.	2.3	1
87	The role of alcohol use and adiposity in serum levels of IL-1RA in depressed patients. <i>BMC Psychiatry</i> , 2022, 22, 158.	2.6	1
88	Severe mental disorders and COVID-19: a one-year systematic review. <i>Nordic Journal of Psychiatry</i> , 0, , 1-1.	1.3	1
89	Differences in psychosocial functioning between psychotic disorders in the Finnish SUPER study. <i>Schizophrenia Research</i> , 2022, 244, 10-17.	2.0	1
90	O5.5. SLEEP IN MAJOR PSYCHIATRIC DISORDERS: RESULTS FROM NATIONWIDE SUPER FINLAND STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S88-S88.	4.3	0

#	ARTICLE	IF	CITATIONS
91	M79 THE INTERPLAY BETWEEN SCHIZOPHRENIA AND INTELLIGENCE POLYGENIC RISK SCORES CONTRIBUTES TO COMMUNITY FUNCTIONING IN PEOPLE WITH PSYCHOTIC DISORDER. <i>European Neuropsychopharmacology</i> , 2019, 29, S209.	0.7	0
92	Importance of congruence between communicating and executing implementation programmes: a qualitative study of focus group interviews. <i>Implementation Science Communications</i> , 2020, 1, 94.	2.2	0
93	Reaction Time and Visual Memory in Connection to Hazardous Drinking Polygenic Scores in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder. <i>Brain Sciences</i> , 2021, 11, 1422.	2.3	0
94	Enhancing the implementation of evidence-based treatment interventions. A comprehensive evaluation of a real-world implementation programme. <i>Nordic Journal of Psychiatry</i> , 0, , 1-1.	1.3	0
95	Adverse childhood experiences and social and occupational functioning in first-episode psychosis " A one year follow - up. <i>Psychiatry Research</i> , 2022, 311, 114502.	3.3	0